Paronychia Clinical Trial
Official title:
A Clinical Study on the Treatment of Paronychia Caused by Afatinib With Zanthoxylum Nitidum Tincture
NCT number | NCT03908892 |
Other study ID # | 2019KT1122 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 12, 2019 |
Est. completion date | December 2022 |
This is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. Enrolled participates will randomly receive original treatment or original treatment plus zanthoxylum nitidum tincture immersion of the sick nail(s).
Status | Recruiting |
Enrollment | 110 |
Est. completion date | December 2022 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Pathologically or cytologically confirmed non-small cell lung cancer; 2. Undergoing treatment with afatinib; 3. With grade 1 paronychia; 4. Age between 18 to 80 years old; 5. Estimated life expectancy of more than months; 6. With the written informed consent. Exclusion Criteria: 1. Paronychia before afatinib treatment; 2. Grade 2 or severer paronychia; 3. Stop using afatinib or with reduced dose of afatinib; 4. Currently diagnosed with severe encephalopathy or psychiatric disorders affecting patients ability of self expression. 5. Has other legal, medical or ethical reasons that patients are not appropriate for clinical study. |
Country | Name | City | State |
---|---|---|---|
China | Guangdong Provincial Hospital of Chinese Medicine | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangzhou University of Traditional Chinese Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Paronychia progress rate | Incidence of grade 2 or more paronychia during paronychia treatment period will be reported. This period will be from randomization till paronychia relief or progression. Frequency of evaluation for paronychia will be everyday. | Through study completion, an average of 10 days. | |
Secondary | Time to paronychia progress | The time elapsed from randomization to either the date of grade 2 or more paronychia occurrence, treatment completion, or last follow-up information. Frequency of evaluation for paronychia will be everyday. | Through study completion, an average of 10 days. | |
Secondary | Time to paronychia relief | The time elapsed from randomization to either the date of paronychia relief, treatment completion, or last follow-up information. Paronychia relief is defined as that paronychia disappears. Frequency of evaluation for paronychia will be everyday. | Through study completion, an average of 10 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06411093 -
Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors
|
N/A | |
Recruiting |
NCT05639933 -
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
|
Phase 2 | |
Completed |
NCT05165082 -
The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study
|
N/A | |
Recruiting |
NCT06140186 -
Efficacy and Safety of Timolol for TKI Induced Paronychia
|
Phase 3 |